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Abstract. Background: Cancer-induced bone pain
remains a serious public health concern, with a need for
translational behavioural tests in order to assess
nociception in preclinical models of this condition.
Burrowing is an innate, ethologically relevant rodent
behaviour that has been proven sensitive to chronic pain
conditions. Herein, we studied for the first time whether
burrowing performance is altered in preclinical models of
cancer-induced bone pain. Materials and Methods: Mice
and rats were inoculated with syngeneic breast cancer
cells. Bone degradation was radiographically evaluated
and nociception was assessed in limb-use and burrowing
tests. Results: Cancer-bearing rodents showed reduced
relative bone density and limb-use scores, confirming
disease development. Burrowing performance decreased
over time in both rodent models. Conclusion: Burrowing
performance was reduced in both rodent models,
indicating that the burrowing test is a relevant and
reproducible behavioural test for assessing disease
development in both mouse and rat models of cancer-
induced bone pain.
Pain is a severe and debilitating symptom of metastatic bone
disease affecting 30-40% of patients with metastatic bone
cancer (1, 2). As cancer-induced bone pain is poorly
controlled with current therapies, preclinical models of this
condition have become an important tool for understanding
the underlying mechanisms of malignant disease and
investigating novel analgesic targets (3). 
The first murine model of localized cancer-induced bone
pain was established through the direct inoculation of cancer
cells into the femoral intramedullary cavity (4). Several
mouse and rat models of metastatic bone disease have been
developed through inoculation of cancer cells in the
intramedullary cavity of long bones, leading to the
identification of novel targets for the treatment of cancer-
induced bone pain (3, 5, 6). 
Traditionally, pain-related behaviour has been assessed
using stimulus-evoked readouts, i.e. tests that measure
involuntary responses to a specific stimulus (thermal or
mechanical). However, the translatability of stimulus-evoked
behavioural tests is currently under debate, as these measure
simple spinal reflexes rather than integrating complex pain-
like behaviours, where cerebral processing of the nociceptive
signal is required (7, 8). Additionally, these tests require
interaction between the experimenter and the animal,
introducing a risk of subjectivity. Therefore, non-stimulus-
evoked tests that evaluate changes in ethologically relevant
rodent behaviours have received growing interest. While
some non-stimulus-evoked tests, such as the limb-use test,
are also highly subjective, an example of an objective,
ethologically relevant behavioural readout is burrowing (9).
Importantly, this innate behaviour can be used to assess the
general well-being of rodents (10) and the reduction in the
amount of substrate voluntarily burrowed can be used as a
surrogate marker of pain-like behaviour (11). As such, the
burrowing test exploits an evolutionary-conserved rodent
behaviour that is not essential for survival in a laboratory
setting; it has thus been hypothesized that this complex
behaviour may be comparable to the “activities of daily
living” in humans (i.e. housekeeping) (10), suggesting that
it might present higher translational validity compared to
stimulus-evoked tests (11).
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To date, the burrowing test has successfully been used to
assess nociception in animal models of inflammatory pain (12-
16), nerve injury-induced neuropathy (12, 17), post-surgical
pain (18), osteoarthritis (19, 20), diabetes-associated neuropathy
(17), HIV-therapy-induced peripheral neuropathy (21), chemo-
therapy-induced mucositis (22, 23), chemotherapy-induced
neuropathy (24) and complex regional pain syndrome (25).
However, the burrowing test has, to our knowledge, never
been used in preclinical models of cancer-induced bone pain.
Therefore, the aim of this study was to evaluate the burrowing
test in mouse and rat models of cancer-induced bone pain.
Materials and Methods
Mouse experiments
Animals. Experiments in the 4T1-Luc2 mouse model of cancer-
induced bone pain were performed at Copenhagen University,
Denmark. Five-week-old male BALB/c (21-25 g; Envigo, Venray,
the Netherlands) mice were housed in groups of four or five in
individually ventilated GM500+ cages (524 cm2) with Tapvei 2HV
bedding (Harjumaa, Estonia). The mice were housed in a
temperature-controlled room (22±2˚C), on a 12/12 light/dark cycle
(lights on at 07:00 AM) and provided water and food (Altromin
1314; Brogaarden, Lynge, Denmark) ad libitum. Environmental
enrichment was provided as an S-brick (Tapvei), paper ropes, a red
translucent shelter and corn hidden in the bedding. Mice were left
to acclimatize to the facility for 1 week prior to initiation of
experiments and animal welfare e.g. body weight, breathing, coat
condition, stool appearance and abnormal behaviours, was regularly
assessed. Mouse experiments were approved by the Danish Animal
Experiments Inspectorate (Copenhagen, Denmark) and carried out
in accordance with the Danish Act on Animal Experiments (LBK
no. 474 of 15/05/2014) and the recommendations and policies of the
International Association for the Study of Pain (26). Experiments
were conducted between April, 2018 and January, 2019. Baseline
behavioural data were obtained for a total of 53 mice used in the
experiments as depicted in Figure 1A; 16 were euthanized due to
post-surgical complications and four (10%) were excluded from the
experimental data due to poor baseline burrowing performance (see
below). All behavioural tests were performed by the same
researcher, blinded to the experimental groups. 
Cell culture. Mouse mammary gland carcinoma cells (4T1-Luc2;
Caliper, Teralfene, Belgium) were cultured as previously described
(27). Briefly, the cells were routinely cultured in RPMI 1640
medium (without phenol red) supplemented with 1% penicillin-
streptomycin and 10% heat-inactivated foetal bovine serum (FBS)
for approximately 10-14 days; cells were split 2 days before surgery.
On the day of surgery, cells were harvested with 0.25% trypsin-
EDTA, re-suspended in Hank Balanced Salt Solution (HBSS) to a
final density of 1.0×106 cells/ml and kept on ice. All reagents were
purchased from Thermo Fisher Scientific, Roskilde, Denmark.
Model of cancer-induced bone pain. Seven-week-old mice were
briefly anaesthetized with 4% isofluorane (Baxter A/S, 100%;
Nomeco, Copenhagen, Denmark) followed by intraperitoneal
administration of a ketamine/xylazine cocktail (85.5 mg/kg
ketamine from Ketaminol vet; MSD Animal Health, Copenhagen,
Denmark; and 12.5 mg/kg xylazine from Nerfasin vet; Virbac,
Kolding, Denmark). Eye ointment (Ophtha A/S, Actavis Group,
Gentofte, Denmark) was applied to the eyes to avoid dehydration.
Thereafter, the inoculation of 4T1-Luc2 cells (or HBSS, sham mice)
was performed as previously described (27). Briefly, mice were
placed on their dorsal side on a heating pad and a small incision
was made on the skin covering the patella ligament of the right hind
limb. The retinaculum tendon was loosened and the patella moved
aside. Next, a 30-G needle was used to drill a hole into the exposed
femoral epiphysis and 1.0×104 4T1-Luc2 cells/10 μl HBSS (n=17)
or vehicle alone for the sham group (10 μl HBSS, n=16) was
injected intramedullary with a 0.3 ml insulin syringe (BD, Apotek,
Copenhagen, Denmark). The bone hole was closed with Ethicon
bone wax (Mediq, Brøndby, Denmark) and the wound irrigated with
saline. The patella was carefully repositioned on top of the distal
femoral epiphyses and two surgical clips (7.5 mm x 1.75 mm,
Agnthos, Lidingö, Sweden) were used to close the surgical wound,
which was covered with a 2% xylocaine gel (AstraZeneca,
Copenhagen, Denmark). Following the surgical procedure, all
animals received 500 μl saline and 0.03 mg/kg buprenorphine
subcutaneously (Temgesic; Indivior UK Limited, Slough, UK). 
Burrowing test. The burrowing test was conducted as previously
described with few modifications (16). Each burrowing tube (200
mm length ×72 mm diameter, raised 30 mm from the ground in the
frontal, open end) was placed in a standard transparent plastic cage
without bedding (125×266×185 mm). Mice underwent a 5-day
training program as follows: Day 1, habituation by placing a pair of
mice in each burrowing cage with an empty burrowing tube; day 2
and 3, training by placing a pair of mice in each burrowing cage
with a burrowing tube filled with 500 g sand (0-3 mm diameter;
ScanSand, Herlev, Denmark), and day 4 and 5, baseline testing by
placing mice individually in each cage with one burrowing tube
filled with 500 g sand. On test days mice were placed individually
in a cage with a burrowing tube filled with 500 g sand; the amount
of sand left in the tube was weighed at the end of each session. All
sessions were conducted for 2 h; cages and burrowing tubes were
assigned to each mouse and remained unchanged throughout the
entire experiment. Ten percent of the mice (n=4) with the lowest
burrowing scores at baseline were excluded from the experiment
and the remaining mice were randomized into the sham (n=16) or
cancer-bearing (n=17) group according to their baseline burrowing
performance; briefly, animals were sorted from highest to lowest in
burrowing performance and sequentially assigned into the different
experimental groups, ensuring that the average baseline amount of
sand burrowed was not significantly different (one-way ANOVA,
p>0.05). All burrowing sessions were conducted between 08:00 AM
and 12:00 PM, on days 5 and 9 after surgery. When several
behavioural tests were conducted on the same day, the order was
the following: limb-use, weight-bearing and burrowing.
Limb-use test. Mice were allowed to individually move freely in a
transparent plastic cage without bedding (125×266×185 mm).
Following 10-min acclimation, the gait of each mouse was observed
for 3 min and scored as follows: 4: Normal use of the affected limb,
3: mild or insignificant limping with normal body distribution, 2:
pronounced or significant limping accompanied by a shift in body
distribution towards the healthy limb, 1: significant limping and partial
lack of use of the affected limb and 0: total lack of use of the affected
limb. Mice were tested before surgery (baseline) and on days 5, 7, 9,
10 and 11 after surgery, between 07:00 and 10:00 AM. A limb-use
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score of 0 was defined as the humane endpoint, and it was reached by
two cancer-bearing mice on day 9, and seven of the cancer-bearing
mice on day 11; all animals were euthanized on day 11.
Weight-bearing test. Mice were individually placed in an
incapacitance tester (Columbus Instruments, Columbus, OH, USA)
with the hind limbs positioned on two separate scales which record
the weight load placed on each limb. Triplicates of 3-s readings
were collected for each animal and the weight-bearing ratio was
calculated as the average weight placed on the right hind limb
divided by the total weight placed on both hind limbs. The test was
conducted before surgery and on day 5, 7, 9, 10 and 11 after
surgery, between 07:00 and 10:00 AM.
X-ray imaging. Upon euthanasia, the right and left hind limbs were
dissected and individually placed in a Lumina XR apparatus (Caliper
Life Sciences, Teralfene, Belgiun), where X-ray images were
obtained. Each image was calibrated to a standard aluminum wedge.
Using ImageJ (1.8.0_112; 64-bit 1.8.0_171; 32-bit; National Institute
of Health, Bethesda, MD, USA), the average mean grayscale value
of two background soft-tissue regions was subtracted from the
grayscale value of the femoral area of interest; all analyses were
performed by a researcher blinded to the experimental groups.
Measurements were then normalized against the standard aluminum
wedge so the readout was relative bone density.
Rat Experiments
Animals. Experiments in the MRMT1-Luc2 rat model of cancer-
induced bone pain were performed at Grünenthal GmbH, Aachen,
Germany. Four-week-old male Sprague Dawley rats (100-124 g;
Janvier Laboratories, Le Genest St Isle, France) were housed in
groups of four or two in individually ventilated 1500U cages (1,500
cm2, Tecniplast) with Lignocel Flake J. bedding (J. Rettenmaier &
Söhne GmbH & Co. KG, Rosenberg, Germany). The rats were
housed in a temperature-controlled room (22±2˚C), on a 12/12
light/dark cycle (lights on at 06:00 AM) and provided water and
food (Ratte/Maus-Haltung; Ssniff, Soest, Germany) ad libitum.
Environmental enrichment was provided as a pure Aspen medium
wood block (Ssniff, Soest, Germany). Rats were left to acclimatize
to the facility for 1 week prior to initiation of experiments and
animal welfare, e.g. body weight, grooming, posture, gait, was
assessed on a daily basis. All experiments were performed according
to the German Animal Welfare Act and were approved by the local
government authority (no. 81-02.05.40.17.087). Experiments were
performed in accordance with the recommendations and policies of
the International Association for the Study of Pain (26).
Experiments were conducted between February and April 2018.
Baseline behavioural data were obtained for a total of 70 rats used
in the experiments as depicted in Figure 1B; one died in surgery, 12
were excluded from analyses due abnormal/lack of tumour growth,
and seven (10%) were excluded due to poor baseline burrowing
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Figure 1. Schematic timeline of the mouse (A) and rat (B) experiments. Mice and rats were left to acclimatize for 1 week upon arrival at the research
institution and thereafter baseline measurements were obtained for the behavioral tests within 1 week. Following cancer-induced bone pain surgery,
rodents were tested in the limb-use (●), weight-bearing (■) and burrowing test (★) on the days indicated in the figure by a researcher blinded to
the experimental groups. When several tests were conducted on the same day, the order was the following: limb-use, followed by weight-bearing
and then burrowing. X-Ray images of the hind limbs were captured post-mortem for the mice, and on days 7, 13 and 19 post-surgery for the rats,
depicted with an X in the figure. 
performance (see below). All behavioural tests were performed by
the same researcher, blinded to the experimental groups.
Cell culture. Rat mammary gland carcinoma cells (MRMT1-Luc2;
Tohoku University, Japan) were cultured as previously described
(28). MRMT1-Luc2 cells were cultured in RPMI 1640 medium
(without phenol red) supplemented with 1% penicillin-streptomycin
and 10% heat-inactivated FBS for approximately 14 days; cells
were split 2 days before surgery. On the day of surgery, cells were
harvested with Detachin (Genlantis, San Diego, CA, USA), re-
suspended in HBSS to a final density of 1.5×106 cells/ml and kept
on ice until use. All reagents were purchased from Thermo Fisher
Scientific.
Model of cancer-induced bone pain. The inoculation of the
MRMT1-Luc2 cells was performed as previously described by Falk
et al. (29). Briefly, approximately 6-week-old animals were
anaesthetized with isoflurane (induction 4%; maintenance
2%±0.5%; Baxter Deutschland GmbH, Unterschleissheim,
Germany) and placed on their dorsal side. The right hind limb was
shaved and disinfected with 70% ethanol prior to making a small
(~1 cm) incision on the skin covering the anterior-medial surface of
the tibia. A hole was made in the tibia using a 0.7 mm drill bit (Fine
Science Tools, Heidelberg, Germany) in order to insert a catheter
into the proximal intramedullary cavity. The catheter was connected
to a 50-μl Hamilton syringe to inject 1.5×104 MRMT1-Luc2
cells/10-μl HBSS (n=50) or vehicle alone (10 μl HBSS for sham
animals, n=20). After removal of the catheter, the hole was closed
using bone restorative material (IRM, Dentsply, PSG Procurement
services GmbH, Lohmar, Germany) and the wound was sutured
(Vicryl sutur 4-0, V292H, FS-2S needle, 45 cm undyed; Johnson &
Johnson medical GmbH, Ethicon Deutschland, Norderstedt,
Germany). Animals received 5 mg/kg carprofen (ReboPharm
GmbH, Bocholt, Germany) subcutaneously 24-h pre-operatively,
peri-operatively and for 2 consecutive days post-surgery and
xylocaine (xylocaine pump spray; ReboPharm GmbH, Bocholt,
Germany) immediately after surgery and on the following 2 days
post-surgery.
Burrowing test. Each burrowing apparatus (320 mm length ×100
mm diameter, raised 60 mm from the ground in the frontal, open
end) was placed in a standard Macrolon type IV cage
(595×380×200 mm; floor area 1820 cm2). The burrowing test was
performed as previously described (9, 30), with small
modifications as described by Rutten et al. (17) and Wodarski et
al. (15). Rats underwent a 4-day training program prior to the
assessment of baseline burrowing performance. The animals were
exposed to the burrowing apparatus in pairs on the first 2 days to
promote social facilitation. On day 1, rats were placed in pairs
with an empty tube for 60 min and on day 2 the same pairs were
adapted to the empty test cage for 30 min, followed by 1 h training
in presence of the burrowing tube, filled with 2500 g gravel (2-4
mm diameter; ORBIT GmbH, Usingen, Germany). When a pair of
rats showed poor burrowing performance (<500 g), individual
animals were exchanged with animals that showed sufficient
burrowing performance (>500 g) and an extra social facilitation
session was conducted. On days 3 and 4, rats were trained
individually by 30-min acclimatization to the empty cage followed
by the introduction of the 2,500 g gravel-filled tube for 1 h. On
day 5, baseline burrowing performance was conducted similarly
to the individual training sessions. Burrowing performance was
calculated as 2,500 g of substrate minus the amount of gravel left
in the tube in the end of each burrowing session. Ten percent of
rats (n=7) with the lowest burrowing scores at baseline were
excluded from the experiment and the remaining rats were
randomized into the sham (n=17) or cancer-bearing (n=33) group
according to baseline burrowing performance. Randomization was
performed by sorting animals according to baseline burrowing
capacity and sequentially assigning them to the experimental
groups, comparing the resulting average baseline amount of gravel
burrowed until no statistical differences between groups were
observed (one-way ANOVA, p>0.05).
All burrowing sessions were conducted between 08:00 AM and
12:00 PM, and burrowing performance was examined on day 8, 17
and 20 after surgery. During the burrowing test no experimenters
were present in the room. If several behavioural tests were
conducted on the same day, limb use was assessed before
burrowing.
Limb-use test. The limb-use test was performed on a daily basis
between 06:00 AM and 10:00 AM, starting on the first day after
surgery. In the limb-use test, rats were taken out of their home cages,
placed in an open space (60 mm × 120 mm) and allowed to move
freely for a maximum of 5 min for behavioural assessment. Scoring
was as follows; 3: Normal use of limb, 2: mild or insignificant
limping with normal body distribution, 1: significant limping with a
shift in body distribution towards the healthy limb, 0: no use of the
affected limb. A limb-use score of 0 was defined as a humane
endpoint (score 0 was reached in one animal; this animal had extra-
tibial tumour growth and was sacrificed 14 days post-surgery). 
X-ray imaging. On days 7, 13 and 19 after surgery, relative bone
density was measured by X-ray densitometry. Animals were shortly
anaesthetized with isoflurane (4% for induction; 2.5% for
maintenance; Baxter Deutschland GmbH) and placed on the dorsal
side in a Lumina XR apparatus (Caliper Life Sciences), with the
operated leg in the capture region. X-ray images of the ipsilateral
leg were captured and relative bone density was analysed using
ImageJ (ImageJ 1.8.0_112; 64-bit; National Institute of Health). The
mean grayscale value of a standard region of interest within the
trabecular bone of the proximal tibia was measured and the average
of two corresponding background regions in the soft tissue proximal
to tibia was subtracted. The relative greyscale value was then
normalized to a standard aluminum wedge for each X-ray image to
calculate the relative bone density. All X-ray analyses were
performed by a researcher blinded to the experimental groups. 
Statistical analyses. Data analyses and plots were generated in
GraphPad Prism 7.03 (rat experiments) or 7.0 (mice experiments)
(Graph Pad Inc, La Jolla, CA, USA); non-parametric data were
analysed in SAS 9.4 (SAS Institute Inc., Cary, NC, USA).
Behavioural data were analysed by 2-way repeated measurements
ANOVA followed Bonferroni corrections for multiple comparisons.
Limb-use (non-parametric) data was analysed by Friedman’s two-
way test, followed by Wilcoxon two-sample test. X-ray images were
analysed by 2-way ANOVA repeated measurements followed by the
Bonferroni method for correction of multiple comparisons (rat
experiments), or by multiple Student’s t-tests followed by the
Bonferroni-Dunn correction for multiple comparisons (mice
experiments). All data are presented as mean±standard error of the
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mean (SEM) and the level of significance was in all cases set to
p<0.05. Based on post-mortem analysis, animals with tumour
growth in the wrong location or without tumours at the end of the
experiment were excluded from analysis (n=12); these included:
extra-tibial tumour growth (n=1), tumour growth in ankle (n=1) and
extinction of the tumour (n=10).  One rat died during surgery and
16 mice were euthanized due to post-surgical complications. 
Results
Cancer-bearing mice present nociceptive behaviour and
bone degradation. Cancer-bearing mice presented a
significant decrease in burrowing performance, compared to
sham mice, 9 days after cell inoculation (p<0.05; Figure
2A). The presence of cancer-induced bone pain behaviour in
4T1-inoculated mice was confirmed by the limb-use and
weight-bearing tests. Cancer-bearing mice presented a
significant decrease in both limb-use scores (p<0.0001;
Figure 2B) and weight-bearing ratio (p<0.0001; Figure 2C)
compared to sham mice, from day 9 after cell inoculation. 
Furthermore, the relative bone density in both ipsi- and
contralateral femurs of sham and cancer-bearing animals was
analysed by X-ray densitometry upon euthanasia. Ipsilateral
cancer-bearing femurs presented a significantly lower
relative bone density than their contralateral matches
(p<0.0001; Figure 2D), while sham femurs presented similar
ipsi- and contralateral relative bone density. 
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Figure 2. The effect of 4T1-Luc cell inoculation in the intrafemoral cavity of mice on burrowing (A) limb-use (B), weight bearing (C) and relative
bone density (D).  Burrowing performance was assessed before surgery and on post-surgical days 5 and 9. The relative bone density of contralateral
and ipsilateral femurs was assessed before surgery and post-mortem (after day 11) (D). Data are presented as means±SEM. Significantly different
at *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 vs. sham; n=16-17. 
Cancer-bearing rats present nociceptive behaviour and bone
degradation. Inoculation of MRMT1-Luc2 cells into the
intrafemoral cavity of rat tibia induced a decrease in
burrowing performance on post-surgical day 20 (p<0.05;
Figure 3A). The presence of cancer-induced bone pain
behaviour in the cancer-bearing rats was confirmed in the
limb-use test from day 11 after surgery (p<0.05 on post-
surgical day 11, p<0.01 on post-surgical day 12, p<0.0001
on post-surgical days 13 to 20; Figure 3B). Furthermore,
tibias from cancer-bearing rats showed a significant decrease
in relative bone density compared to those from sham mice,
from post-surgical day 13 (p<0.0001; Figure 3C).
Discussion 
The aim of this study was to examine whether burrowing
performance is a feasible readout for assessing cancer-
induced bone pain in mice and rats. While stimulus-evoked
behavioural tests have been traditionally used in preclinical
pain research (31-35), it has been argued that they rely on
spinal and bulbospinal pathways, which are measures of
simple reflexes to nociceptive stimuli as a means to prevent
harm, compared with multi-modal and voluntarily altered
behavioural traits occurring as a result of induced
nociception, e.g. well-being of the animal or nest building
(7, 8). In this context, the burrowing test is considered more
ethologically relevant compared to stimulus-evoked readouts,
thereby presenting higher translational validity for the
preclinical assessment of pain-related behaviour (11-13, 15-
20, 24, 36-38). 
The present study is the first to test burrowing
performance in rodent cancer-induced bone pain models. For
that purpose, syngeneic breast cancer cells were inoculated
in the intramedullary cavity of the femur or tibia of
immunocompetent mice and rats, respectively; in order to
confirm disease progression, the limb-use test and X-ray
densitometry were performed in both species and
additionally weight bearing was assessed in mice (6, 27). In
both cancer-bearing mice and rats, the cancer-induced bone
pain phenotype developed as expected and was consistent
with previous studies (6, 39, 40). 
In rodent models of cancer-induced bone pain, development
of a pain-related phenotype in the limb-use test has been
shown to coincide with decreases in stimulus-evoked tests,
e.g. von Frey and Randall Selitto, and non-stimulus-evoked
tests, e.g. weight bearing and grid climbing (28, 29, 41, 42).
In accordance with this, our data showed a decrease in
burrowing performance in cancer-bearing mice parallel to the
development of limb-use impairment and a shift in weight
distribution. Furthermore, burrowing performance also
decreased in cancer-bearing rats over time compared with
sham rats. However, the burrowing performance of the cancer-
bearing rats was not impaired to the same extent as previously
reported in inflammatory and neuropathic pain models (11, 12,
16, 20), despite having similar baseline levels. Moreover,
compared to the mouse experiment, rats developed a more
subtle pain-like phenotype in burrowing compared with the
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Figure 3. The effect of MRMT1-Luc2 cell inoculation in the intratibial
cavity of rats on burrowing (A), limb use (B) and relative bone density
(C). Data are presented as means±SEM. *p<0.05, **p<0.01,
***p<0.001, ****p<0.0001 vs. sham; n=17-33 per group.
limb-use test; it remains unclear whether this difference is
species-specific or related to the site of cancer cell inoculation
(tibia vs. femur). It is important to note, however, that only
male adolescent rodents were included in this study, thus
hindering general conclusions on the extent and efficacy of
burrowing behaviour as a surrogate marker of cancer-induced
bone pain in older and in female rodents. 
Recently, a prospective multicentre study showed that is
possible to use burrowing behaviour as a robust and reliable
readout to assess pain-related behaviour in a Complete
Freund’s Adjuvant rat model of inflammatory pain, across
laboratories (15). This demonstrates that burrowing is robust
and reproducible when standardized by the same protocol,
model and species. Herein, we examined for the first time
whether burrowing is an appropriate behavioural test for the
assessment of well-being in two different species at two
different laboratories. Our study shows that cancer-induced
bone pain induces a decrease in burrowing behaviour, and
we suggest that burrowing may be a useful addition to the
battery of available behavioural tests for the detection of
well-being in rodent models of cancer-induced bone pain. 
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